CT is increasingly being used to stage and quantify the extent of diffuse lung diseases both
in clinical practice and in treatment trials. The role of CT in the assessment of patients …

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …

Objective The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic
sclerosis (SSc) has hampered an evidence‐based approach to treatment. This RCT was …

1. INTRODUCTION 1.1 An overview of the ILD guideline Since the publication of the first
BTS guidelines for diffuse lung disease nearly 10years ago, 1 the specialty has seen …

Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite
recent advances in the treatment is, at present, the major cause of death. Today, an early …

Objective: To analyse the durability of the responses after haematopoietic stem cell
transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high …

Rationale: The Scleroderma Lung Study II (SLS II) demonstrated significant improvements in
pulmonary function and dyspnea at 24 months compared with baseline when patients with …

The connective tissue disorders (CTDs), also called collagen vascular diseases (CVDs),
represent a heterogeneous group of immunologically mediated inflammatory disorders with …

Current therapeutic modalities for the treatment of systemic sclerosis (SSc) have significant
limitations. The window of opportunity to prevent tissue fibrosis and irreversible damage …

Objective. To find an effective, safe immunosuppressive regimen as an alternative to
cyclophosphamide (Cy) for the treatment of clinically evident diffuse scleroderma (dSSc) …